Potassium channels in nervous tissue.
There is a multiplicity of potassium channels in nervous tissue. These have been characterized on the basis of their electrophysiological actions but more information is required on their structures and on the functions of the different subtypes of channel in different parts of the nervous system. We currently also lack drugs which are specific in opening or closing individual subtypes of channel. However, when more is known about the structure and function of these channels and when more specific modulators of their activity are available, it is likely that the use of such compounds may be of great value in the treatment of a variety of conditions affecting the nervous system, including epilepsy, the damage due to cerebral anoxia, neurodegenerative disorders and demyelinating disorders.
Aronson
J K
JK
MRC Unit, Radcliffe Infirmary, Oxford, U.K.
D015761:4-Aminopyridine / Q000494:pharmacology; D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology; D002220:Carbamazepine / Q000494:pharmacology; D019806:Cromakalim; D004553:Electric Conductivity / Q000187:drug effects; D009420:Nervous System / Q000378:metabolism*; D010276:Parasympatholytics / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism*; D011758:Pyrroles / Q000494:pharmacology; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000494:pharmacology
D001578:Benzopyrans; D010276:Parasympatholytics; D015221:Potassium Channels; D011758:Pyrroles; D013757:Tetraethylammonium Compounds; D019806:Cromakalim; D002220:Carbamazepine; D019789:Tetraethylammonium; D015761:4-Aminopyridine